{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/prescribing-information/topical-miotics/","result":{"pageContext":{"chapter":{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics","depth":2,"htmlHeader":"<!-- begin field 13bd5ce8-1c9f-4406-b4fe-5af8cf9ad825 --><h2>Topical miotics</h2><!-- end field 13bd5ce8-1c9f-4406-b4fe-5af8cf9ad825 -->","summary":"","htmlStringContent":"<!-- begin item 3f4f9b7c-a8c5-4dc2-84f2-441cb3e7a097 --><!-- end item 3f4f9b7c-a8c5-4dc2-84f2-441cb3e7a097 -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8cc13b3d-532e-50c6-bb63-eb0f358d2cf3","slug":"available-preparations","fullItemName":"Available preparations","depth":3,"htmlHeader":"<!-- begin field d4e172b6-4218-452b-913d-f6dd136a877e --><h3>Which topical miotics are licensed in the UK for the treatment of glaucoma?</h3><!-- end field d4e172b6-4218-452b-913d-f6dd136a877e -->","summary":"","htmlStringContent":"<!-- begin item 0c8e1cbb-d7b9-4d6d-acbd-377723f20927 --><!-- begin field 8b6e1746-08b3-4ad9-8f52-b058811d0a9d --><ul><li>The only topical miotic licensed in the UK for the treatment of glaucoma is pilocarpine hydrochloride. </li><li>The usual dose is one drop up to four times daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 8b6e1746-08b3-4ad9-8f52-b058811d0a9d --><!-- end item 0c8e1cbb-d7b9-4d6d-acbd-377723f20927 -->","subChapters":[]},{"id":"9aa735a1-c072-50a0-9706-808330143ca1","slug":"action","fullItemName":"Action","depth":3,"htmlHeader":"<!-- begin field 6b247106-e978-4c75-b742-6e0440ebcc0e --><h3>How do topical miotics work?</h3><!-- end field 6b247106-e978-4c75-b742-6e0440ebcc0e -->","summary":"","htmlStringContent":"<!-- begin item 8daf03d2-e136-4157-b3ee-db23c41771d1 --><!-- begin field d8236379-e5cb-494e-a1e8-2f8e905b0eba --><ul><li>Topical miotics are primarily used for angle closure glaucoma where the drug-induced miosis pulls the iris away from the trabecular meshwork to allow improved drainage of aqueous humour. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field d8236379-e5cb-494e-a1e8-2f8e905b0eba --><!-- end item 8daf03d2-e136-4157-b3ee-db23c41771d1 -->","subChapters":[]},{"id":"7e50537d-fc1f-5f6a-b5a9-9a57bfc69990","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8069beee-2fa2-4240-a370-e5b654469d9f --><h3>What key adverse effects are associated with topical miotics?</h3><!-- end field 8069beee-2fa2-4240-a370-e5b654469d9f -->","summary":"","htmlStringContent":"<!-- begin item dbbc8661-d295-484b-890f-dc359f3d5ed0 --><!-- begin field eb3bc012-3317-4edc-bf3e-a11c38a2c11c --><ul><li><strong>Local adverse effects of pilocarpine eye drops include:</strong><ul><li>Burning, itching, lacrimation, and smarting.</li><li>Brow ache, loss of accommodation, and blurred vision.</li><li>Conjunctival vascular congestion.</li><li>Myopia.</li><li>Vitreous haemorrhage and pupillary block.</li><li>Lens changes have also been reported with long-term use.</li><li>Retinal detachment.</li><li>Allergic reaction to the active drug or preservative.</li></ul></li><li><strong>Systemic adverse effects are rare at normal doses.</strong> However, when high doses are given (for example in the treatment of acute angle closure glaucoma), the risks of systemic adverse effects are increased.<ul><li>Systemic adverse effects may include hypotension, bradycardia, bronchial spasm, pulmonary oedema, salivation, sweating, nausea, vomiting, headache, and diarrhoea.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field eb3bc012-3317-4edc-bf3e-a11c38a2c11c --><!-- end item dbbc8661-d295-484b-890f-dc359f3d5ed0 -->","subChapters":[]},{"id":"09daa55c-f81e-5016-9b82-6a2275a92817","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field f9247dd2-f524-49db-9e55-e61f2b6fa84b --><h3>What drug interactions are important with topical miotics?</h3><!-- end field f9247dd2-f524-49db-9e55-e61f2b6fa84b -->","summary":"","htmlStringContent":"<!-- begin item 583c8d39-0c79-4e40-b8cc-63ae59366395 --><!-- begin field bde11d57-2b1b-492b-b4e2-208e744b7f8f --><ul><li>There are no known common drug interactions with pilocarpine eye drops.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2016c</a>]</p><!-- end field bde11d57-2b1b-492b-b4e2-208e744b7f8f --><!-- end item 583c8d39-0c79-4e40-b8cc-63ae59366395 -->","subChapters":[]},{"id":"d55911b9-0245-50ee-ae02-a63c3c59035c","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 2f3649be-48af-4d70-80e5-8fdb2ada8431 --><h3>What are the cautions and contraindications when prescribing topical miotics?</h3><!-- end field 2f3649be-48af-4d70-80e5-8fdb2ada8431 -->","summary":"","htmlStringContent":"<!-- begin item a7a5f457-e126-4754-90b6-589246fae920 --><!-- begin field a68bdd0d-c4f6-41d6-b8a5-b9246bf28b00 --><ul><li>Use is contraindicated in people with acute iritis and anterior uveitis.</li><li>Systemic reactions rarely occur with pilocarpine eye drops when treating chronic glaucoma at normal doses. However, when treating acute angle closure glaucoma the dose is usually higher and the possibility of systemic reactions must be considered. Caution is particularly advised in people with heart failure, asthma, peptic ulceration, hypertension, urinary tract obstruction, Parkinson's disease, and corneal abrasions.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field a68bdd0d-c4f6-41d6-b8a5-b9246bf28b00 --><!-- end item a7a5f457-e126-4754-90b6-589246fae920 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}